Phase IB Dose Escalation Study of Bortezomib (VELCADE) Administered Weekly for 4 Weeks and Sunitinib (SU-011248) Administered Daily for 4 Weeks Followed by a 14 Day Rest in Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2014
At a glance
- Drugs Bortezomib (Primary) ; Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 25 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Jun 2010 Results from 24 evaluable patients presented at ASCO.